Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality

The British Journal of Dermatology
John R IngramVincent Piguet

Abstract

More than 50 interventions have been used to treat hidradenitis suppurativa (HS), and so therapy decisions can be challenging. Our objective was to summarize and appraise randomized controlled trial (RCT) evidence for HS interventions in adults. Searches were conducted in Medline, Embase, CENTRAL, LILACS, five trials registers and abstracts from eight dermatology conferences until 13 August 2015. Two review authors independently assessed study eligibility, extracted data and assessed methodological quality. Primary outcomes were quality of life and adverse effects of the interventions. Twelve trials, from 1983 to 2015, investigating 15 different interventions met our inclusion criteria. The median trial duration was 16 weeks and the median number of participants was 27. Adalimumab 40 mg weekly improved the Dermatology Life Quality Index (DLQI) by 4·0 points, which equates to the minimal clinically important difference for the scale, compared with placebo (95% confidence interval -6·5 to -1·5 points). Evidence quality was reduced to 'moderate' because the results are based on only a single study. Adalimumab 40 mg every other week was ineffective in a meta-analysis of two studies comprising 124 participants. Infliximab 5 mg kg(-1...Continue Reading

References

Jun 1, 1983·International Journal of Dermatology·O J Clemmensen
Dec 8, 1998·Journal of the American Academy of Dermatology·G B Jemec, P Wendelboe
Jul 15, 2005·JAMA : the Journal of the American Medical Association·John P A Ioannidis
Dec 2, 2008·Evidence-based Medicine·Holger J SchünemannGordon H Guyatt
May 15, 2009·Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]·Emily TierneyIltefat Hamzavi
May 19, 2010·Archives of Dermatology·David R AdamsBryan E Anderson
Jul 27, 2011·Plastic and Reconstructive Surgery·Lyndsey HightonJ K G Laitung
Jan 13, 2012·The New England Journal of Medicine·Gregor B E Jemec
Dec 19, 2012·Annals of Internal Medicine·Alexa B KimballGregor B E Jemec
Jun 7, 2014·The British Journal of Dermatology·J R IngramT Clarke
Jan 24, 2015·Dermatology : International Journal for Clinical and Investigative Dermatology·M K A BasraA Y Finlay
Feb 3, 2015·Journal of the European Academy of Dermatology and Venereology : JEADV·C C ZouboulisG B E Jemec
Apr 29, 2015·The British Journal of Dermatology·J R Ingram, M McPhee

❮ Previous
Next ❯

Citations

Dec 18, 2016·Journal of the American Academy of Dermatology·Henri MontaudiéThierry Passeron
Jun 24, 2017·Journal of Cutaneous Medicine and Surgery·Afsaneh AlaviYves Poulin
Jun 21, 2018·Revista do Colégio Brasileiro de Cirurgiões·Rogério Rafael DA Silva MendesRolf Gemperli
Oct 31, 2018·Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Società Italiana Di Dermatologia E Sifilografia·Gautham VellaichamyIltefat H Hamzavi
Dec 27, 2018·The British Journal of Dermatology·Z N OvadjaO Lapid
Jun 6, 2019·Anais Brasileiros De Dermatologia·Renata Ferreira MagalhãesAndrea Machado Coelho Ramos
Mar 29, 2019·The British Journal of Dermatology·R M NielsenG B Jemec
Jan 8, 2020·Contact Dermatitis·Lindsey M VollerErin M Warshaw
May 30, 2019·American Journal of Clinical Dermatology·Kelsey S FloodAlexa B Kimball
Jul 4, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·L H GergelyF Rencz
Dec 1, 2017·Expert Opinion on Investigational Drugs·Peter Theut RiisGregor B Jemec
Aug 25, 2020·JAMA Surgery·Judy HamadBradley D Figler
May 11, 2019·American Journal of Clinical Dermatology·Georgios NikolakisChristos C Zouboulis
Jun 14, 2019·Therapeutic Advances in Chronic Disease·Kevin T SavageAlexa B Kimball
Jun 15, 2021·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·Sophia ZimmerEsther von Stebut
Aug 28, 2021·Cells·Emanuele ScalaGabriella Fabbrocini
Dec 25, 2019·Actas dermo-sifiliográficas·T Gracia CazañaY Gilaberte

❮ Previous
Next ❯

Methods Mentioned

BETA
profiler

Software Mentioned

Cochrane
GRADEpro
GRADE

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

The Cochrane Database of Systematic Reviews
John R IngramVincent Piguet
The Cochrane Database of Systematic Reviews
Ausama AtwanVincent Piguet
© 2022 Meta ULC. All rights reserved